Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Inclusion Criteria:

• Chronic hepatitis C, genotype 4-infection (hepatitis C virus [HCV] ribonucleic acid [RNA] level greater than 1,000 IU/mL at Screening)
• Subjects must meet one of the following:
• Treatment-naive: Subject has never received antiviral treatment for HCV infectionOR
• Treatment Experienced (Prior null responders, Partial responders or Relapsers topegylated-interferon [pegIFN]/RBV);
• Females must be post-menopausal, of non-child bearing potential or practicing specificforms of birth control
• In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy orFibroscan
• In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscanwith Child-Pugh score less than or equal to 6 at Screening and confirmed absence ofhepatocellular carcinoma

Exclusion Criteria:

• Females who are pregnant or breastfeeding
• Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virusantibody
• HCV genotype performed during screening indicating unable to genotype or co-infectionwith any other HCV genotype
• abnormal laboratory tests
• self-reports current drinking more than 2 drinks per day
• current enrollment in another investigational study
• previous treatment with a direct acting antiviral agent (DAA) containing regimen
• In substudy 1, evidence of liver cirrhosis
• In substudy 2, evidence of current or past Child-Pugh B or C classification andconfirmed presence of hepatocellular carcinoma